Survival Extension

In a presentation at the European Society for Medical Oncology, researchers reported that Roche's Perjeta (pertuzumab) could extend patients' lives, the New York Times reports.

According to lead researcher Sandra Swain from the MedStar Washington Hospital Center, patients who received the drug, which treats metastatic breast cancer, had a median survival time 16 months longer than those in the control group.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.